DrugPatentWatch Database Preview
Join the DrugPatentWatch Referral Program Get access to a free drug patent landscape report or a free one-month subscription
« Back to Dashboard
Fasudil is an investigational drug.
There have been 10 clinical trials for Fasudil. The most recent clinical trial was a Phase 3 trial, which was initiated on July 1st 2019.
The most common disease conditions in clinical trials are Motor Neuron Disease, Amyotrophic Lateral Sclerosis, and Heart Failure. The leading clinical trial sponsors are Shahid Beheshti University of Medical Sciences, Brigham and Women's Hospital, and Colorado State University.
There are eight hundred and forty-one US patents protecting this investigational drug and eight international patents.
Recent Clinical Trials for Fasudil
|Early Intracoronary Administration of Fasudil in the Primary PCI of ST-segment-Elevation Myocardial Infarction||RenJi Hospital||Phase 4|
|Fasudil Eye Drop in Retinopathy Of Prematurity(ROP)||Shahid Beheshti University of Medical Sciences||Phase 2/Phase 3|
|Inhibition of Rho Kinase (ROCK) With Fasudil as Disease-modifying Treatment for ALS||University Medical Center Goettingen||Phase 2|
Top disease conditions for Fasudil
Top clinical trial sponsors for Fasudil
|Drugname||Patent Number||Patent Title||Patent Assignee||Estimated Expiration|
|Fasudil||Start Trial||Ethylsulfonated hyaluronic acid biopolymers and methods of use thereof||The Regents of the University of California (Oakland, CA)||Start Trial|
|Fasudil||Start Trial||Use of anthelmintic agents against Dirofilaria immitis||Intervet Inc. (Madison, NJ)||Start Trial|
|Fasudil||Start Trial||Diarylimidazole compound and harmful organism control agent||Nippon Soda Co., Ltd. (Tokyo, JP)||Start Trial|
|Fasudil||Start Trial||Minimal volume reprogramming of mononuclear cells||Fate Therapeutics, Inc. (San Diego, CA)||Start Trial|
|Fasudil||Start Trial||Alkynyl pyridine-substituted amide compound and pesticide||Nissan Chemical Industries, Ltd. (Chiyoda-ku, JP)||Start Trial|
|Fasudil||Start Trial||Corneal thickness modulating agent||KOWA COMPANY, LTD. (Nagoya-shi, JP)||Start Trial|
|>Drugname||>Patent Number||>Patent Title||>Patent Assignee||>Estimated Expiration|
|Drugname||Country||Document Number||Estimated Expiration||Related US Patent|
|Fasudil||European Patent Office||2981556||2033-04-02||Start Trial|
|Fasudil||World Intellectual Property Organization (WIPO)||2014165513||2033-04-02||Start Trial|
|Fasudil||European Patent Office||3177291||2034-07-11||Start Trial|
|>Drugname||>Country||>Document Number||>Estimated Expiration||>Related US Patent|